Cargando…

The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics

The understanding of etiology and pathogenesis of idiopathic immune myositis is fast evolving, and so is the classification of myositis subtypes. The diversity in genetics, major histocompatibility complex expressions, immunohistochemical, and specific and associated autoantibodies not only explains...

Descripción completa

Detalles Bibliográficos
Autor principal: Patwardhan, Anjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034746/
https://www.ncbi.nlm.nih.gov/pubmed/32128294
http://dx.doi.org/10.7759/cureus.7049
_version_ 1783499935631540224
author Patwardhan, Anjali
author_facet Patwardhan, Anjali
author_sort Patwardhan, Anjali
collection PubMed
description The understanding of etiology and pathogenesis of idiopathic immune myositis is fast evolving, and so is the classification of myositis subtypes. The diversity in genetics, major histocompatibility complex expressions, immunohistochemical, and specific and associated autoantibodies not only explains the individual variability in response to therapies but also begs for subtype-specific treatments. With the evolution of the new biological therapies, the treatment of idiopathic immune myositis (IIM) has greatly transformed in recent years. This article appraises the current therapeutic value of intravenous immunoglobulin (IVIg) in idiopathic immune myopathy patients in the era of transformed treatment options. This article argues why the IVIg therapy still retains its value as an unreplaceable treatment option in certain specific subtypes of idiopathic immune myositis patients as well as in certain specific clinical idiopathic immune myositis scenarios.
format Online
Article
Text
id pubmed-7034746
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-70347462020-03-03 The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics Patwardhan, Anjali Cureus Pediatrics The understanding of etiology and pathogenesis of idiopathic immune myositis is fast evolving, and so is the classification of myositis subtypes. The diversity in genetics, major histocompatibility complex expressions, immunohistochemical, and specific and associated autoantibodies not only explains the individual variability in response to therapies but also begs for subtype-specific treatments. With the evolution of the new biological therapies, the treatment of idiopathic immune myositis (IIM) has greatly transformed in recent years. This article appraises the current therapeutic value of intravenous immunoglobulin (IVIg) in idiopathic immune myopathy patients in the era of transformed treatment options. This article argues why the IVIg therapy still retains its value as an unreplaceable treatment option in certain specific subtypes of idiopathic immune myositis patients as well as in certain specific clinical idiopathic immune myositis scenarios. Cureus 2020-02-19 /pmc/articles/PMC7034746/ /pubmed/32128294 http://dx.doi.org/10.7759/cureus.7049 Text en Copyright © 2020, Patwardhan et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pediatrics
Patwardhan, Anjali
The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title_full The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title_fullStr The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title_full_unstemmed The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title_short The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics
title_sort value of intravenous immunoglobulin therapy in idiopathic inflammatory myositis in the current transformed era of biologics
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034746/
https://www.ncbi.nlm.nih.gov/pubmed/32128294
http://dx.doi.org/10.7759/cureus.7049
work_keys_str_mv AT patwardhananjali thevalueofintravenousimmunoglobulintherapyinidiopathicinflammatorymyositisinthecurrenttransformederaofbiologics
AT patwardhananjali valueofintravenousimmunoglobulintherapyinidiopathicinflammatorymyositisinthecurrenttransformederaofbiologics